Hypothyroidism affects approximately 2-5% of the UK population and can make weight loss more challenging due to its effects on metabolism (how much energy we burn each day)
It also enables accurate in vivo monitoring of CAR-T cell expansion, providing insights into treatment efficacy
Also noteworthy earlier this month was the publication of a Phase 2 randomized trial in 272 participants without diabetes of orforglipron, an oral GLP-1 agonist, which achieved a 14.7% weight loss (placebo-adjusted 12.3%) at the highest dose With that brief review of the latest trials and drugs, lets turn to clinical outcomes, for which most are taking us back to single agonistGLP-1drugs
International Urology and Nephrology 2016 48:8 (1305-1312)
Microdosing involves using lower, subtherapeutic doses of compounded GLP-1/GIP formulations combined with multiple active ingredients including GLP1/GIP working together
GLP-1 medications are contraindicated during pregnancy